Recommendation 1

2.83    The committee recommends that the government ensure that the Therapeutic Goods Administration continues to carry out comprehensive, appropriate and timely consultations with industry and other key stakeholders, particularly in relation to legislation and regulations affecting the Therapeutic Goods Administration regulatory framework.

Recommendation 2

2.85    The committee notes the importance of self-regulatory models and recommends that the Therapeutic Goods Administration investigate ways to better support the effective functioning of self-regulatory models by industry, including the potential for further strengthening of the penalties regime if needed.

Recommendation 3

2.87    The committee recommends that the government ensure that the Therapeutic Goods Administration is adequately resourced in accordance with its cost-recovery framework so that it is able to carry out its surveillance and monitoring functions in relation to advertising compliance.

Recommendation 4

2.90    The committee recommends that the Senate pass the bills.

Navigation: Previous Page | Contents | Next Page